drugset
drugset / Trial / NCT03748745

A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects

NCT03748745 ↗

Phase 1 Completed 28 enrolled Nanjing Sanhome Pharmaceutical, Co., Ltd.
Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the drug-drug interaction of SH229 tablets and Daclatasvir dihydrochloride tablets. The study also evaluates the pharmacokinetics and tolerability of co-administration of SH229 tablets and Daclatasvir dihydrochloride tablets in healthy subjects. This study provides evidence for the designing of following clinical trial protocols.

Timeline

Start
2018-11-19
Primary completion
2018-12-25
Completion
2018-12-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Daclatasvir Small molecule 60 mg Oral
Subject SH229 Unknown 600 mg Oral

Indications

No indication recorded.